
Direct Answer: EN ISO 10993 is the series of standards for evaluating the biological safety of medical devices. ISO 10993-1 sets the framework, within a risk management process, and later parts cover specific tests and assessments. It is a conformity framework, not a registrar certificate. Demonstrating compliance follows 5 steps: Preparation (device categorisation by body contact and duration), Documentation (biological evaluation plan and characterisation), Testing (only the endpoints needed, at competent laboratories), Internal Review (gap closure and risk file update) and Reporting & Submission (biological evaluation report in your regulatory file). Typical programmes take 3–18 months depending on device risk.
EN ISO 10993 is the family of standards for the biological evaluation of medical devices. It helps manufacturers show that device materials and finished products do not cause unacceptable biological harm, such as toxicity, irritation, sensitisation or blood-related reactions. The European EN ISO adoption is what notified bodies reference under EU rules, while the international ISO version is widely used elsewhere.
Biological evaluation sits inside your wider compliance system: a ISO 13485 quality management system, ISO 14971 risk management and, for many manufacturers, ISO 9001 processes. This guide explains the full route from device categorisation to the biological evaluation report. See also partnership evaluation criteria and business verification for supplier due diligence.
This guide is for regulatory affairs managers, quality and R&D leads, and device manufacturers, as well as component and material suppliers who are asked for biocompatibility data. It covers the evidence-based route and the consultant-led route. Related reading: supplier collaboration platforms and distributors and manufacturers.
EN ISO 10993 is a series titled Biological evaluation of medical devices. ISO 10993-1 describes the evaluation and testing within a risk management process, covering device categorisation, relevant biological endpoints and the need for a structured evaluation. Other parts cover specific tests (such as cytotoxicity and sensitisation), chemical characterisation, toxicological risk assessment and sample preparation. The current edition of Part 1 is recent, so check the latest status on the ISO and CEN catalogues before planning. The approach is risk-based: you use existing data first and test only where gaps remain.
Regulators in many regions, including those applying EU and US requirements, expect a biological evaluation aligned with ISO 10993.
The series is designed to identify biological hazards early, before devices reach patients.
Material data, chemical characterisation and toxicological assessment can reduce unnecessary testing and animal use.
A well-run biological evaluation protects patients and speeds regulatory review. Gains depend on device type and how early you start, so plan evaluation during design, not at the end.
A complete evaluation reduces regulator and notified body questions and avoids late-stage retesting.
Early material and chemistry choices prevent costly redesigns after a failed test.
Biocompatibility data from material suppliers makes qualification of components easier.
Chemical characterisation and toxicological assessment support defensible, data-driven conclusions.
The plan defines who owns materials, testing, assessment and sign-off.
Links biological hazards to your risk management and post-market activities.
The series is large and parts are updated at different times. The table lists the main parts used in most programmes. Always confirm current editions and any European (EN) adoptions on the official catalogues.
| Part | Title / Focus | What It Means for You |
|---|---|---|
| ISO 10993-1 | Evaluation and testing within a risk management process | Framework: categorise the device, identify endpoints, plan the evaluation. |
| ISO 10993-3 | Genotoxicity, carcinogenicity and reproductive toxicity | Tests for genetic and long-term effects where required. |
| ISO 10993-4 | Interactions with blood | Haemocompatibility testing for blood-contacting devices. |
| ISO 10993-5 | In vitro cytotoxicity | A common first screening test of cell toxicity. |
| ISO 10993-6 | Local effects after implantation | Evaluation of tissue response to implanted materials. |
| ISO 10993-10 | Skin sensitisation | Assesses allergic response potential. |
| ISO 10993-11 | Systemic toxicity | Assesses effects beyond the contact site. |
| ISO 10993-12 | Sample preparation and reference materials | How to prepare device samples and extracts for testing. |
| ISO 10993-17 | Toxicological risk assessment of constituents | Establishes allowable limits for leachable substances. |
| ISO 10993-18 | Chemical characterisation of materials | Identifies and quantifies chemical constituents; may replace some biological tests. |
| ISO 10993-23 | Tests for irritation | Covers irritation testing, including in vitro approaches. |
Preparation defines what you are evaluating. Categorise the device by nature of body contact (surface, external communicating or implant) and contact duration (limited, prolonged or long-term), because these determine the biological endpoints to address. Allow 2–6 weeks.
Make sure regulatory, quality and R&D staff understand Part 1 and the risk-based approach.
Biological evaluation needs budget, lab capacity and design-change authority. Align with your ISO 13485 management review.
List all materials, additives, coatings, processing aids, sterilisation methods and manufacturing residues.
Determine contact type and cumulative duration, including multiple uses.
Compare existing data (supplier certificates, literature, prior tests) with required endpoints.
Assign owners, laboratories and timelines, and set up links to the risk file.
Choosing materials with known biocompatibility history can remove entire test categories. If a change in material or process occurs later, reassess the evaluation. See also ISO 14971 for managing design changes through risk.
Documentation shows an evaluator how you reached your conclusions. Keep it traceable: each endpoint should link to evidence or a justification.
| Document | Description | Key Consideration |
|---|---|---|
| Biological Evaluation Plan (BEP) | Defines device, categorisation, endpoints, existing data and planned testing. | Approve before testing starts and update when the design changes. |
| Material & Process Description | Full list of materials, suppliers and manufacturing and sterilisation steps. | Include residues such as cleaning agents and EO. |
| Chemical Characterisation Report | Identifies extractables and leachables, often per Part 18. | Can reduce or replace some biological tests. |
| Toxicological Risk Assessment | Assesses chemical constituents against allowable limits, often per Part 17. | Performed by a qualified toxicologist. |
| Test Reports | Laboratory results for selected endpoints. | Check laboratory accreditation and test method versions. |
| Biological Evaluation Report (BER) | Summarises data, justifies conclusions and states residual risk. | Must be linked to the risk management file. |
| Supplier Documentation | Material declarations and change-notification agreements. | Use verified suppliers; see business verification. |
| Records | Change history, reviews, approvals and re-evaluation triggers. | Keep retrievable under document control. |
DO: justify every endpoint, whether tested or not.
DON’T: copy supplier certificates without checking that they match your final, sterilised device.
Use templates for the BEP and BER and keep them consistent with your technical file. Contract clarity matters too; see manufacturer-distributor contracts.
Testing should be targeted. Start from the plan, use chemical characterisation to reduce the number of tests where acceptable, and use competent laboratories.
Typical endpoints include cytotoxicity, sensitisation, irritation, systemic toxicity, genotoxicity, haemocompatibility and implantation, depending on category.
Test final, finished, sterilised devices or justified representative samples, following Part 12.
Run extractables studies to identify risks early and potentially avoid animal tests.
Use ISO/IEC 17025-accredited, GLP-compliant laboratories where required.
Follow the principle of replacement, reduction and refinement and consider validated in vitro methods.
Keep raw data, protocols, deviations and final reports under document control.
Investigate root cause, assess material or process changes, and retest as needed.
Before reporting, review the complete evidence set against the plan. Check that every endpoint is addressed, that tested samples represent the final device, that toxicological conclusions are supported, and that residual risks are fed into your risk management file. Reviewers should be independent of the people who generated the data.
Confirm each planned endpoint has data or a documented justification.
Involve toxicologists, regulatory and quality staff with relevant competence.
Verify that samples reflect final materials, processing and sterilisation.
Resolve open findings and repeat tests where needed before reporting.
Transfer conclusions and residual risks to your ISO 14971 file.
An external regulatory consultant can pre-review the report before submission.
The biological evaluation report (BER) is the final record. It is normally reviewed by a notified body or regulator as part of your technical documentation. There is no separate ISO 10993 certificate; acceptance is through regulatory review.
| Stage | What Happens | Key Focus |
|---|---|---|
| Finalise the BER | Summarise data, justify conclusions and state residual risk. | Traceability from endpoint to evidence. |
| Integrate with Risk File | Link conclusions to hazards and controls. | Consistency with ISO 14971 |
| Quality System Review | Confirm procedures and records meet ISO 13485 requirements. | Document control and change management. |
| Regulatory Review | Technical documentation reviewed by a notified body or regulator. | Responding to questions with evidence. |
| Maintenance | Re-evaluate on design, material, supplier or process changes and from post-market data. | Ongoing conformity. |
Keep a clear index of the evidence, make the toxicologist available for questions and prepare answers on material changes. Related standards you may be asked about include ISO 9001 and ISO 14001.
These ranges are indicative only. Get written quotes and a laboratory schedule before committing to a launch date.
| Factor | Impact on Cost | Impact on Timeline |
|---|---|---|
| Contact Type & Duration | Implants and long-term devices need more endpoints. | Long-term devices may need 12–18 months or more. |
| Existing Data | Strong supplier and historical data reduces testing. | Can cut months from the plan. |
| Number of Materials | More materials increase characterisation effort. | Longer extraction and analysis schedules. |
| Chemical Characterisation | Adds upfront cost but may avoid biological tests. | Typically several weeks to months. |
| In Vivo Studies | Substantially higher cost. | Study length and lab availability drive timing. |
| Consultant Support | Adds fees; reduces rework. | Experienced toxicologists shorten review cycles. |
If you hold ISO 13485 or ISO 9001, reuse document control, supplier control and CAPA processes for the evaluation.
Look for ISO/IEC 17025 accreditation covering the test methods you need, and GLP compliance where required.
Choose labs familiar with your device type and sterilisation method.
Confirm that your regulator or notified body accepts the laboratory’s reports.
Compare scope, turnaround, retest policy and report quality.
Multi-region submissions may benefit from labs with international recognition.
Responsive study directors and clear protocols reduce delays. See partnership evaluation criteria.
ISO 14971 is the risk management standard for medical devices, and ISO 10993-1 places biological evaluation inside that process. Biological hazards such as toxicity, sensitisation and degradation products are identified, evaluated and controlled, and residual risk is judged acceptable or not. Both rely on a quality system like ISO 13485, and information security of device and test data may fall under ISO 27001 and ISO 27701.
Derive hazards from materials, additives, processing and use conditions.
Use test data and toxicological assessment to judge severity and acceptability.
Change materials, processes or labelling, or add controls where risk is not acceptable.
Running a standard battery wastes money. Avoid: write the BEP first.
A supplier change can invalidate data. Avoid: require change notification and reassess.
Unsterilised or prototype samples may not reflect the final device. Avoid: justify representativeness.
Reports without toxicological assessment can be rejected. Avoid: integrate chemistry and risk assessment.
Unverified suppliers undermine evidence; see global partner service. Avoid: qualify suppliers formally.
Conclusions must flow into the risk file. Avoid: cross-reference clearly. See risk allocation.
A sound biological evaluation depends on reliable materials and suppliers. GTsetu complements your compliance work by connecting you with verified manufacturers, distributors and suppliers of medical device materials and components.
Related Articles
ISO 9001 Certification
Quality management foundation for document control and audits.
ISO 14001 Certification
Environmental management for manufacturing and sterilisation processes.
ISO 13485 Certification
Medical device quality management system that houses your biological evaluation.
ISO 27001 Certification
Information security for design, test and supplier data.
ISO 45001 Certification
Occupational health and safety, including laboratory and production safety.
ISO 22000 Certification
Food safety management, relevant to contact-material suppliers.
ISO 20000 Certification
IT service management supporting regulated data systems.
ISO 27701 Certification
Privacy information management for personal and clinical data.
ISO 26262 Certification
Functional safety for automotive and device electronics partners.
ISO 22301 Certification
Business continuity for resilient medical device supply chains.
ISO 14971 Certification
Risk management for medical devices, the framework for ISO 10993-1.
Partnership Evaluation Criteria
Framework for evaluating and selecting business partners.
Connect with verified manufacturers, distributors and suppliers on GTsetu: compliance-backed verification, anonymous discovery, built-in NDA workflows and zero broker commissions.
Find Verified Partners Free →Browse Verified Companies
They represents the product, and research team behind GTsetu, a global B2B collaboration platform built to help companies explore cross-border partnerships with clarity and trust. The team focuses on simplifying early-stage international business discovery by combining structured company profiles, verification-led access, and controlled collaboration workflows.
With a strong emphasis on trust, and disciplined engagement, Team GTsetu shares insights on global trade, partnerships, and cross-border collaboration, helping businesses make informed decisions before entering deeper commercial discussions.